Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0023418 (
leukemia
)
93,477
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The cell line HDLM-2 was established from the pleural effusion of a patient with Hodgkin's disease. Here, we describe the morphological, cytochemical, enzymological, immunological, molecular biological, and functional characteristics of the cell line. The results of this multiparameter profile show that HDLM-2 is different from other well-studied
leukemia
-lymphoma cell lines including other Hodgkin's disease derived cell lines. HDLM-2 cultures contain mainly mono- or binucleated cells, but also prominent giant cells with two to ten nuclei. HDLM-2 cells do not express an immunophenotype characteristic of a given cell lineage. However, the cells are positive for Ki-1, HeFi-1, Leu-M1, Tac, and HLA class II markers. Cytochemical, enzymological, and functional data are equally inconclusive, but are definitely not compatible with a monocyte/macrophage profile. Analysis of the gene status documents that T-cell receptor beta- and gamma-chain genes are rearranged while
immunoglobulin heavy chain
genes are in germline configuration. The combined results indicate a T-cell origin of HDLM-2 cells. The evidence available from this and other established Hodgkin's disease derived cell lines suggests a lymphoid origin of Hodgkin and Reed-Sternberg cells.
...
PMID:Characterization of Hodgkin's disease derived cell line HDLM-2. 260 52
The development and isotype distribution of Moloney murine
leukemia
virus (M-MuLV)-specific serum antibodies following primary inoculation with Moloney murine sarcoma/
leukemia
virus (M-MuSV/M-MuLV) in adult BALB/c mice have been investigated using an enzyme-linked immunosorbent assay (ELISA). The primary antibody responses to M-MuSV/M-MuLV consisted of the IgM, IgG2a, IgG2b, and
IgG3
isotypes; no M-MuLV-specific serum IgG1 or IgA antibodies were detected. The detectable antibody response was biphasic, with an early peak of virus-specific titers seen between 10 and 15 days after inoculation and a second peak seen in regressor sera. Pooled regressor sera contained IgM, IgG2a, and IgG2b antibodies which bound to M-MuLV-expressing lymphoma cells. Immunoelectron microscopy with regressor sera showed IgG bound both to infected cell surfaces and to mature viral particles, while IgM bound only to infected cell surfaces. These findings were supported by immunoprecipitation analyses which demonstrated binding of the M-MuLV-specific antibodies to both virion-associated and cell-associated antigens encoded by the gag and env genes.
...
PMID:Isotype distribution and specificity of the antibody response to primary Moloney murine sarcoma virus infection in BALB/c mice. 267 79
We have analyzed the oncogene rearrangements involving BCL2 and MYC in the
leukemia
cells of a patient with an aggressive prolymphocytic leukemia that had an abnormal karyotype including a t(14;18) translocation and a chromosome 17q+. Molecular analysis showed that BCL2 was rearranged in the major breakpoint cluster region and had joined into the
immunoglobulin heavy chain
gene as in follicular lymphoma. Cloning and sequence analysis of the rearranged MYC gene revealed that MYC was truncated at the Pvu II site at the end of the first exon of MYC and had joined into the regulatory elements of a gene that we called BCL3 (B-cell leukemia/lymphoma 3). The BCL3 locus was mapped to chromosome 17 band q22. We found BCL3 transcribed as a message of 1.7 kilobases in many hematopoietic cell lines representing all hematopoietic lineages. In the patient's
leukemia
cells, the truncated MYC gene was highly expressed under the influence of BCL3 regulatory elements, leading to an aggressive B-cell
leukemia
that presumably had been derived from an indolent lymphoma carrying a rearranged BCL2 gene.
...
PMID:Activation of MYC in a masked t(8;17) translocation results in an aggressive B-cell leukemia. 268 63
A case of congenital
leukemia
that originally did not express any lineage-specific antigenic markers is presented. The blast cell morphologic appearance was L1 according to French-American-British (FAB) classification and showed lymphoid characteristics by cytochemical staining and transmission electron microscopy. However, immunophenotyping using a variety of monoclonal antibodies did not confirm the lymphoid origin. Furthermore, the
immunoglobulin heavy chain
and T-cell receptor beta-chain genes were in germ-line configuration. The in vitro culture study defined the
leukemia
as of myeloid origin. The semisolid methylcellulose culture showed an acute non-lymphocytic leukemia-type growth pattern. Bone marrow blasts underwent myeloid differentiation with positive myeloperoxidase and butyrate esterase activity during a suspension culture. These findings indicate that this case represents an acute undifferentiated leukemia that has probably arisen from the malignant transformation of stem cells of myeloid progeny.
...
PMID:Identification of myeloid origin in undifferentiated congenital leukemia by in vitro marrow culture study. 278 65
We have detected and cloned two rearrangements in the T-cell receptor alpha locus from a clone of somatic cell hybrids carrying a t(14;14)(q11;q32) chromosomal translocation derived from an ataxia telangiectasia patient with T-cell chronic lymphocytic leukemia. The T-cell clone carrying the t(14;14) chromosomal translocation was known to be present for greater than 10 years before the onset of overt
leukemia
. One molecular rearrangement of the T-cell receptor alpha locus corresponded to a functional variable-joining region (V-J) joining, whereas the other derived from the breakpoint of the t(14;14)(q11;q32) translocation. Chromosomal in situ hybridization of the probe derived from the t(14;14) breakpoint localized the breakpoint region to 14q32.1, apparently the same region that is involved in another ataxia telangiectasia characteristic chromosome translocation, t(7;14)(q35;q32). The 14q32.1 breakpoint is at least 10,000 kilobase pairs (kbp) centromeric to the
immunoglobulin heavy chain
locus. Sequence analysis of the breakpoint indicates the involvement of a J alpha sequence during the translocation. Comigration of high-molecular weight DNA fragments involved with t(7;14) and t(14;14) translocations suggests the presence of a cluster of breakpoints in the 14q32.1 region, the site of a putative oncogene, TCL1.
...
PMID:Molecular analysis of a t(14;14) translocation in leukemic T-cells of an ataxia telangiectasia patient. 278 89
Tumor cell DNA derived from different lymphoid organs of 30 rats serially inoculated at birth with Moloney murine
leukemia
virus (MoMuLV) was examined by Southern blot analysis and hybridization to the following DNA probes: MoMuLV long terminal repeat (LTR), Moloney
leukemia
virus integration regions 1, 2, 3, and 4 (Mlvi-1, Mlvi-2, Mlvi-3, and Mlvi-4), T-cell receptor beta locus, and
immunoglobulin heavy chain
locus. This analysis revealed that the tumors segregating in different lymphoid organs in 10% of the animals were clonally unrelated. These findings are consistent with the hypothesis that the MoMuLV-induced rat thymic lymphomas are polyclonal in origin. At least two factors may be responsible for this phenomenon: (i) increase in the number of the available target cells in virus-infected animals, and (ii) genetic instability associated with provirus integration in the developing premalignant clones.
...
PMID:Induction of multiple independent T-cell lymphomas in rats inoculated with MOloney murine leukemia virus. 278 11
The BCL2 (B cell lymphoma/
leukemia
-2) and C-MYC oncogenes become activated by chromosomal translocations involving the
immunoglobulin heavy chain
locus in human follicular lymphomas and Burkitt lymphomas, respectively. Though much is known about the biological actions of C-MYC, little information is available concerning the functions of BCL2, particularly in human B cells. Using a gene transfer approach we contrasted the effects of deregulated BCL2 and C-MYC expression in a human EBV-immortalized B cell line GM607B. Both BCL2 and C-MYC enhanced the ability of GM607B cells to grow in reduced serum and in limiting dilution cultures. These findings provide direct evidence that BCL2 can alter the growth characteristics of human B lymphocytes, thus strengthening arguments for its role in the pathogenesis of human lymphomas.
...
PMID:Deregulated BCL2 expression enhances growth of a human B cell line. 278 59
Leukemic blasts from 40 consecutively admitted adults with untreated acute lymphoblastic leukemia (ALL) were examined for myeloid surface antigen expression. Of these, 14 (35%) were reactive with one or more myeloid monoclonal antibodies. Each example of myeloid surface antigen-positive (My+ ALL) met the standard morphologic and cytochemical criteria for ALL. In addition, none of the 13 samples studied for ultrastructural evidence of myeloperoxidase met the criteria for acute myelocytic leukemia (AML). All patient samples reacted with lymphoid monoclonal antibodies: CD10+ (8 patients), CD19+ CD10- (2 patients), T cell+ (2 patients), and T cell+ CD10+ (2 patients). Coexpression of myeloid and lymphoid determinants was established by two-color immunofluorescence studies using flow cytometry in five of five samples analyzed. Cytogenetic abnormalities that have been associated with myeloid and mixed leukemias were common, including t(9;22), 7q-, abnormalities of 11q with or without a translocation, 20q-, and -5. Blasts from seven patients were studied at the molecular level. Immunoglobulin heavy chain gene rearrangements were detected in five of five samples with B cell+ T cell- phenotypes. One sample that was T cell+ CD10+ was germline for the
immunoglobulin heavy chain
and the T cell receptor gamma- and beta-chain genes. The other patient with T cell+ CD10+ blasts relapsed with AML following allogeneic bone marrow transplantation. The
leukemia
cells at the time of diagnosis and the cells at relapse demonstrated similar cytogenetics and the same immunoglobulin gene rearrangement, suggesting a clonal relationship. As a group, the My+ ALL patients had a significantly decreased complete remission rate when compared to My- ALL patients. Further studies at the molecular level will be required to determine the significance of karyotype abnormalities in My+ ALL.
Leukemia
1989 Nov
PMID:Myeloid surface antigen-positive acute lymphoblastic leukemia (My+ ALL): immunophenotypic, ultrastructural, cytogenetic, and molecular characteristics. 281 78
Immunoglobulin and T cell receptor gene rearrangement and expression were investigated within B cell acute lymphoblastic leukemias (ALLs) that are thought to be representative of the early stages of normal human B cell development. Although the
immunoglobulin heavy chain
locus is rearranged in leukemic cells from all of these patients, only cells from pre-B ALL patients express mu chain protein. We have shown, however, that
immunoglobulin heavy chain
transcripts are expressed at levels similar to those found in normal B cells in all of these leukemic cell types and, in addition, some of the leukemias with a more mature phenotype also express immunoglobulin light chain mRNA. In contrast, leukemic cells which had rearranged T cell receptor gamma chain genes were not found to express gamma chain transcripts, indicating that the transcription of immunoglobulin and T cell receptor genes in these cells may be regulated in a lineage-specific manner.
Leukemia
1989 Nov
PMID:Immunoglobulin and T cell receptor gene rearrangement and expression in B cell acute lymphoblastic leukemia. 281 80
Specific human monoclonal anti-CMV antibodies have been isolated and characterized. The first patient had a chronic T cell lymphocytic
leukaemia
and a subclinical CMV infection developed at the same time as a monoclonal peak of kappa
IgG3
. The purified F (ab')2 fragment of the
IgG3
had an intense anti-CMV activity. A second monoclonal antibody, also a kappa
IgG3
, was isolated in a non-immunodepressed patient with a primary CMV infection (chronic pyrexia and hepatitis). The immunotransfer showed that the anti-CMV IgM and IgG of the patient's serum reacted particularly with the p51 protein of virus capsid. The monoclonal
IgG3
was specific for the same p51. The third monoclonal anti-CMV Ig studied was synthesized in vitro by the B lymphocytes of a renal transplant patient immortalized by the Epstein-Barr virus. This kappa IgM produced continuously reacted strongly with the nucleus of the cells infected by the CMV. Human monoclonal anti-CMV antibodies could be used for the early detection of viral antigens by immunofluorescence and might also be used to treat severe cases of CMV infection.
...
PMID:[Human monoclonal anti-cytomegalovirus antibodies]. 282 59
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>